Reaction
Mucosal Disorder reporting signals
As of the last recalculation, Mucosal Disorder appears in 980 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 43.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 19 | 43.1 | 43.2 |
| Mesna Injection | 10 | 26.0 | 26.0 |
| Mesna | 10 | 25.5 | 25.5 |
| Meperidine Hydrochloride | 9 | 20.9 | 20.9 |
| Amphotericin B | 11 | 18.8 | 18.9 |
| Granisetron Hydrochloride | 9 | 18.5 | 18.5 |
| Granisetron | 9 | 18.4 | 18.4 |
| Ado-Trastuzumab Emtansine | 7 | 17.8 | 17.8 |
| Fludarabine Phosphate | 25 | 13.8 | 13.8 |
| Panitumumab | 10 | 13.7 | 13.7 |
| Posaconazole Delayed-Release | 7 | 13.6 | 13.6 |
| Busulfan | 10 | 13.6 | 13.6 |
| Melphalan | 14 | 13.2 | 13.3 |
| Azacitidine For | 10 | 11.8 | 11.8 |
| Dronedarone | 5 | 10.5 | 10.5 |
| Pertuzumab | 13 | 10.3 | 10.3 |
| Alpelisib | 4 | 9.8 | 9.8 |
| Upadacitinib | 33 | 8.9 | 8.9 |
| Docetaxel Anhydrous | 27 | 8.7 | 8.7 |
| Docetaxel | 27 | 8.7 | 8.7 |
| Obinutuzumab | 6 | 7.8 | 7.8 |
| Azacitidine | 10 | 7.2 | 7.2 |
| Durvalumab | 6 | 6.3 | 6.3 |
| Cabozantinib | 12 | 5.4 | 5.4 |